Research programme: Werner syndrome helicase inhibitors - Breakpoint Therapeutics
Latest Information Update: 31 Jul 2023
At a glance
- Originator Breakpoint Therapeutics
- Class Antineoplastics
- Mechanism of Action Werner syndrome helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Jul 2023 Preclinical trials in Solid tumours in Germany (unspecified route) before July 2023 (Breakpoint Therapeutics pipeline, July 2023)